Jetstream Venture Fund announced an investment in Wonderlab Bio, a Boston-based biotechnology company focused on off-the-shelf cell therapies. The investment expands Jetstream’s portfolio of high-growth companies across sectors, including regenerative medicine, aerospace, and artificial intelligence.
Wonderlab Bio is developing regenerative medicine therapies using induced pluripotent stem cells (iPSCs) sourced from HLA-homozygous “super donors.” The company’s approach is designed to create cell therapies that can be broadly matched to patient populations without requiring systemic immunosuppression. Traditional patient-specific cell therapies can cost between $50,000 and $500,000 and are often limited by immune rejection concerns.
The company’s lead program targets knee osteoarthritis, a condition affecting more than 32 million Americans. Wonderlab Bio is developing an injectable iPSC-derived chondrocyte therapy aimed at regenerating cartilage without surgery. The company said the treatment is expected to cost less than a traditional joint replacement procedure.
Wonderlab Bio also noted that its platform has demonstrated cartilage repair in preclinical animal studies and is part of a $42 million ARPA-H regenerative medicine program. The company added that its donor bank currently covers more than 90% of the U.S. population and could support future therapies in cardiac disease and neurodegeneration.
Jetstream Venture Fund is managed by Xcellerant Ventures and Sweater Industries LLC and is structured as an interval fund designed to provide broader investor access to venture-backed companies.
KEY QUOTES:
“Wonderlab’s approach to HLA-matching is a complete paradigm shift for treating chronic conditions. By removing the need for immunosuppression and drastically lowering manufacturing costs, they are unlocking the potential of cell therapy for tens of millions of patients who currently have no regenerative options.”
Chris Yoo, Portfolio Manager, Jetstream Venture Fund
